Patents by Inventor Jan zur Megede

Jan zur Megede has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10287620
    Abstract: Methods of determining polymerase fidelity are provided. In one embodiment, the method comprises filling a gapped plasmid with a polymerase to form a gap-filled plasmid, wherein the gap-filled plasmid comprises a gene encoding an protein that is functional or non-functional depending on the polymerase fidelity; forming a plurality of partitions from a solution comprising the gap-filled plasmid and a label for detecting the presence of the plasmid; detecting the presence of the gap-filled plasmid in one or more of the partitions; and determining the fidelity of the polymerase by determining a ratio of partitions containing the gene encoding a functional protein to partitions containing a gene encoding a non-functional protein.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: May 14, 2019
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Man Cheng, Xiangdong Meng, Jan Zur Megede
  • Publication number: 20180238865
    Abstract: Methods of detecting an analyte in a sample are provided. In one embodiment, the method comprises forming a partition comprising the sample, a binding agent capable of emitting a signal when bound to the analyte, and a marker capable of identifying the partition; allowing the binding agent to bind to the analyte, if present; and detecting the presence of the analyte in the sample by detecting the signal emitted from the binding agent in the partition.
    Type: Application
    Filed: August 18, 2016
    Publication date: August 23, 2018
    Applicant: Bio-Rad Laboratories, Inc.
    Inventors: Jan Zur Megede, George Karlin-Neumann
  • Patent number: 10048256
    Abstract: Sample analysis systems and methods are provided.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: August 14, 2018
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Jan zur Megede
  • Publication number: 20170314060
    Abstract: Methods of determining polymerase fidelity are provided. In one embodiment, the method comprises filling a gapped plasmid with a polymerase to form a gap-filled plasmid, wherein the gap-filled plasmid comprises a gene encoding an protein that is functional or non-functional depending on the polymerase fidelity; forming a plurality of partitions from a solution comprising the gap-filled plasmid and a label for detecting the presence of the plasmid; detecting the presence of the gap-filled plasmid in one or more of the partitions; and determining the fidelity of the polymerase by determining a ratio of partitions containing the gene encoding a functional protein to partitions containing a gene encoding a non-functional protein.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 2, 2017
    Inventors: Man CHENG, Xiangdong MENG, Jan ZUR MEGEDE
  • Patent number: 9598469
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: March 21, 2017
    Assignees: Novartis Vaccines and Diagnostics, Inc., University of Stellenbosch
    Inventors: Jan Zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse Van Rensberg, Thomas J. Scriba
  • Publication number: 20160274097
    Abstract: Sample analysis systems and methods are provided.
    Type: Application
    Filed: March 17, 2016
    Publication date: September 22, 2016
    Inventor: Jan zur Megede
  • Patent number: 9234181
    Abstract: Strategies for increasing the productivity of alphavirus packaging cell lines and of reducing the possibility that replication competent virus may be generated during large scale production of recombinant alphavirus particles.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: January 12, 2016
    Assignee: Novartis AG
    Inventors: Zequn Tang, Jan zur Megede
  • Publication number: 20140220060
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Application
    Filed: December 26, 2013
    Publication date: August 7, 2014
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Jan ZUR MEGEDE, Susan BARNETT, Ying LIAN, Susan ENGELBRECHT, Estrelita Janse VAN RENSBERG, Thomas J. SCRIBA
  • Patent number: 8637044
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: January 28, 2014
    Assignee: Novartis AG
    Inventors: Susan Barnett, Rino Rappuoli, Victoria A Sharma, Indresh K Srivastava, Jan Zur Megede
  • Patent number: 8541230
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Gag- and/or Env-containing proteins are also described.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: September 24, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc
    Inventors: Susan W. Barnett, Jan Zur Megede
  • Patent number: 8518694
    Abstract: A nucleic acid vector comprising: (i) a promoter; (ii) a sequence encoding a HML-2 polypeptide operably linked to said promoter; and (iii) a selectable marker. Preferred vectors comprise: (I) a eukaryotic promoter; (ii) a sequence encoding a HML-2 polypeptide downstream of and operably linked to said promoter, (iii) a prokaryotic selectable marker; (iv) a prokaryotic origin of replication; and (v) a eukaryotic transcription terminator downstream of and operably linked to said sequence encoding a HML-2 polypeptide. Vectors of the invention are particularly useful for expression of HML-2 polypeptides either in vitro (e.g. for later purification). Or in vivo (e.g. for nucleic acid immunization). They are well suited to nucleic acid immunization against prostrate tumors. A preferred HML-2 is PCAV, which is located in chromosome 22 at 20.428 megabases (22q11.2).
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: August 27, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Stephen Hardy, John Donnelly, Jan zur Megede
  • Publication number: 20120269840
    Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.
    Type: Application
    Filed: April 27, 2012
    Publication date: October 25, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS. INC.
    Inventors: Susan W. BARNETT, Jan ZUR MEGEDE, Indresh SRIVASTAVA, Ying LIAN, Karin HARTOG, Hong LIU, Catherine GREER, Mark SELBY, Christopher WALKER
  • Publication number: 20120269851
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Application
    Filed: February 17, 2012
    Publication date: October 25, 2012
    Applicants: University of Stellenbosch, NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg, Thomas J. Scriba
  • Patent number: 8263394
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: September 11, 2012
    Assignee: Novartis Vaccines & Diagnostics Inc.
    Inventors: Jan zur Megede, Susan W. Barnett
  • Publication number: 20120183557
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 19, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS. INC.
    Inventors: Susan BARNETT, Rino RAPPUOLI, Victoria A. SHARMA, Indresh K. SRIVASTAVA, Jan ZUR MEGEDE
  • Patent number: 8173137
    Abstract: The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these vectors and sequences along with methods of using these vectors and sequences are also disclosed.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: May 8, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Jan Zur Megede, Susan W. Barnett
  • Patent number: 8168194
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Grant
    Filed: February 3, 2006
    Date of Patent: May 1, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Susan Barnett, Rino Rappuoli, Victoria A. Sharma, Indresh K. Srivastava, Jan Zur Megede
  • Patent number: 8168418
    Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 1, 2012
    Inventors: Susan W Barnett, Jan Zur Megede, Indresh Srivastava, Ying Lian, Karin Hartog, Hong Liu, Catherine Greer, Mark Selby, Christopher Walker
  • Patent number: 8133494
    Abstract: The invention relates to polynucleotides encoding modified immunogenic HIV-1 South African subtype C Env polypeptides. The modifications to the Env polypeptides include deletions of V1, V2 and the stem region. The expression cassettes may be used, for example, to express the encoded polypeptide. A recombinant expression system for use in a selected host cell comprising an expression cassette encoding for the modified HIV-1 Env polypeptide is also described.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: March 13, 2012
    Assignee: Novartis Vaccine & Diagnostics Inc
    Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg, Thomas J. Scriba
  • Publication number: 20110236469
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Gag- and/or Env-containing proteins are also described.
    Type: Application
    Filed: May 16, 2011
    Publication date: September 29, 2011
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Susan W. BARNETT, Jan Zur Megede